Introduction
In addition to its clearly established role in malignant disease, recent observations suggest that angiogenesis is also important in obesity. Obesity is associated with expansion of the capillary bed in regional fat depots. Treatment of obese mouse models with antiangiogenic agents is associated with a dose-dependent, reversible reduction in adipose tissue 1 suggesting that regulation of adipose tissue vasculature is an important component of obesity. Furthermore, obese patients with several types of cancers have worse prognosis, decreased disease-free interval after initial treatment and increased risk of metastatic disease, [2] [3] [4] suggesting that angiogenesis may be enhanced in obesity.
Adipose tissue contains abundant endothelial cells and these cells, adipocytes or other cell types present in adipose tissue secrete angiogenic factors, such as vascular endothelial growth factor (VEGF) 5 and HGF 6 that can function in both an autocrine/paracrine fashion as well as having endocrine effects in other organ systems. Adipose tissues may also express antiangiogenic factors such as angiostatin and endostatin. Recently adiponectin, a hormone produced by adipocytes that sensitizes tissues to insulin, 7 has also been shown to have potent antiangiogenic activity involving caspase-mediated endothelial cell apoptosis. 8 Serum adiponectin levels are reduced in obese subjects. 9, 10 Angiogenesis is controlled by a balance between angiogenic factors or factors which stimulate endothelial cell proliferation and migration and antiangiogenic factors which inhibit these processes. A wide variety of growth factors have been shown to have angiogenic activity in various assay systems. Many of these factors are expressed in adipose tissue and in addition to any local effects they have in adipose tissue, they may have effects in other capillary beds and contribute to endothelial dysfunction and cardiovascular disease, both of which have been linked to obesity. For example, both HGF and VEGF are expressed in adipose tissue and both of these have been implicated in pathogenesis of cardiovascular disease. [11] [12] [13] In addition to effects on endothelial cells in capillary beds many of the same factors are important in lymphangiogenesis and may therefore have a role in the development of cancer metastasis. While VEGF 14 and HGF 15 have been reported to be elevated in obese patients there are very few data on other angiogenic and antiangiogenic factors in obese patients. Consequently we investigated the levels of VEGF, VEGF-C, VEGF-D, soluble VEGF receptor-2 (sVEGFr2), HGF, angiopoietin-2, angiogenin and endostatin concentrations in lean and obese subjects. Although other angiogenic growth factors and inhibitors have been described we chose to examine the above because of the availability of reliable, sensitive assays. In addition, adiponectin, leptin and parameters of insulin resistance were also measured to determine whether any relationship existed between these parameters and angiogenic factors and endostatin.
Methods

Material and methods
Subjects.
A total of 58 lean subjects, 24 males and 34 females were studied. Subjects were considered lean if their BMI was less than 25 kg/m 2 . The overweight and obese group consisted of 42 individuals, 16 males and 28 females. Participants in the study were recruited from healthy volunteers and patients attending obesity clinics at Charles University. Informed consent was obtained from all subjects. The study protocol was approved by the Research Ethic Committee of Charles University. All participants provided written informed consent. Obese subjects were screened for diabetes using an oral glucose tolerance test. The WHO diagnostic criteria were used to interpret the oral glucose tolerance test. Subjects found to have diabetes were excluded. Blood was collected after an overnight fast. Serum was prepared, stored in aliquots at À701C and transported on dry ice to the University of Manitoba where the assays were performed.
Assays. Blood glucose was determined immediately after sampling using a standard automated glucose oxidase method. Insulin, leptin and adiponectin were determined in duplicates in one run using radioimmunoassays from Linco Research, Inc. (St Charles, MO, USA) with intra-assay coefficient of variation (CV) 5, 6.3 and 8.7%, respectively. VEGF, VEGF-D, sVEGFR-2, HGF, angiopoietin-2, angiogenin and endostatin were measured according to manufacturer's instructions with Quantikine immunoassays (R&D Systems, Inc., Minneapolis, MN, USA) with intra-assay CV 2.7, 7.2, 1.7, 6.8, 7, 2.9, 3 and interassay CV 11.5, 5.95, 7.3, 6.3, 3, 9.9 and 10%, respectively. VEGF-C was measured with enzyme immunoassay purchased from IBL Co., Ltd. (Fujioka-City, Japan) with intra-assay CV 3.2% and interassay CV 9.7%. Insulin resistance was calculated using homeostasis model assessment insulin resistance index (HOMA-R). 16 Statistical analysis. All data are expressed as the mean7-s.e.m. Statistical analysis was performed using a two-tailed ttest for comparison between two groups. For comparisons between multiple groups ANOVA followed by Dunnett's ttest was used. Multivariate linear regression analysis was used to determine correlation coefficients between various parameters. Prior to regression analysis, data were tested for normality of distribution by the Shapiro-Wilk test and consequently BMI, insulin, HOMA-R, leptin, HGF, VEGF-D, angiopoietin-2 and endostatin were log transformed to obtain normal distributions.
Results
The characteristics of the two study populations are shown in Table 1 . Although the overweight and obese subjects were slightly older than the lean subjects, these differences were Significance differences between lean and overweight and obese subjects of the same gender, significant at Po0.005. b Significance differences between lean and overweight and obese subjects of the same gender, significant at Po0.05.
c Significance differences between lean and overweight and obese subjects of the same gender, significant at Po0.01. Significant difference between gender groups, significant at Po0.01. e Significant difference between gender groups, significant at Po0.005.
f Significant difference between gender groups, significant at Po0.05.
Endothelial growth factors in obesity JV Silha et al not statistically significant. Furthermore, we subsequently examined age as a possible confounding variable in multivariate linear analysis and found that this difference in age was unimportant in our overall interpretation of the data. As anticipated overweight and obese subjects also had significantly higher glucose, insulin, leptin and HOMA-R values than lean controls with the exception that the difference in insulin levels between lean and overweight female subjects did not achieve statistical differences. Adiponectin was significantly lower in female obese subjects compared to lean subjects. Leptin and adiponectin concentrations demonstrated sexual dimorphism with female lean subjects having significantly higher levels than male lean subjects consistent with previous reports. 10, 17 Despite comparable BMI, female overweight and female obese subjects had significantly higher leptin levels than respective male subjects (Table 1) . When all subjects were considered sexual dimorphism was observed in serum concentrations of VEGF-C, VEFG-D and angiopoietin-2 levels. Levels of these proteins were significantly higher in female than male subject, Po0.001, Po0.001 and P ¼ 0.033, respectively. Furthermore, when lean and overweight groups are considered together, a comparable group in terms of mean age (46.3 vs 47 y for males and females, respectively) and mean BMI (24.1 vs 22.6 kg/m 2 for males and females, respectively), there was a significant gender differences in mean VEGF-D and VEGF-C levels (398753 vs 746793, Po0.005 and 10.270.6 vs 12.770.7, Po0.02) between male and female subjects. However, when individual subgroups were considered, the only gender difference that achieved significance was the higher levels of VEGF-D observed in lean female subjects compared to lean male subjects. When all subjects regardless of gender were considered, VEGF, VEGF-C, VEGF-D, sVEGF-R2, angiopoietin-2, angiogenin and endostatin were significantly elevated in overweight and obese compared to lean individuals. The differences between the two groups were more marked in female subjects. When individual gender groups were considered, significant differences were seen between lean and overweight male subjects for endostatin and angiogenin and between endostatin levels in lean and overweight female subjects (Figure 1) . VEGF-D, sVEGRr2 and angiogenin levels were significantly elevated in obese males compared to lean male subjects while these parameters and angipoietin-2, VEGF-C and endostatin were also significantly elevated in female obese subjects compared to lean female subjects. There was no significant difference in HGF levels between the two groups of subjects.
Positive correlations between BMI and serum concentrations of VEGF-C, VEGF-D, sVEGF-R2, angiopoietin-2, and angiogenin were observed even after adjustment for both gender and age (Table 2) . Among these parameters, angiogenin showed the strongest correlation with BMI ( Figure 2 ). Serum concentrations of endostatin, VEGF and HGF showed only weak correlations with BMI. As previously reported leptin showed a strong positive correlation, and adiponectin showed a weak negative correlation with BMI. 18, 19 After adjustment for age, gender and BMI, insulin concentrations correlated positively with leptin (P ¼ 0.001) and negatively with adiponectin (P ¼ 0.009), but insulin did not correlate with any of the other measured parameters. Insulin resistance, measured as HOMA-R, did not significantly correlate with any of the angiogenic factors or endostatin levels but did correlate negatively with adiponectin (P ¼ 0.012). When either male and female subjects were considered separately or together there was no significant correlation between age and any of the angiogenic factors or endostatin.
Discussion
While adipose tissue has previously been considered simply to be a repository of excess energy stored as triglycerides, more recently it has been appreciated that adipose tissue has important effects on other organs such as the brain, liver and the reproductive system and modulates many metabolic processes. These effects are mediated via proteins, which act both locally in a paracrine or autocrine manner but also have endocrine functions. Some of these proteins, which are expressed almost exclusively in adipose tissue, for example, adiponectin and leptin are now referred to as adipokines or adipocytokines, whereas others demonstrate less tissuespecific expression and may be more appropriately considered to be cytokines. Some of these cytokines have effects on endothelial cells and have angiogenic activity or function as inhibitors of angiogenesis.
Adipose tissue is composed of many different cell types and in many situations it remains unclear which cell types are responsible for expression of a particular cytokine expressed in fat tissue. Endothelial cells are abundant in adipose tissue and an expansion of the capillary bed appears to be necessary for the development of obesity. 20 Antiangiogenic therapy is accompanied by remodeling of adipose tissue capillary beds and a reduction in fat mass in rodents. 1, 21 Furthermore, there is circumstantial evidence from epidemiological surveys that suggests that angiogenesis may be enhanced in human obesity. Obesity has been reported by many 3,22-24 but not all investigators 25, 26 to increase the risk of tumor progression and metastatic disease in patients with breast cancers. The situation in prostate cancer is more complex since the risk of prostate cancer in obese men is lower than lean men possibly because of the lower testosterone levels associated with obesity. 27 However, obesity was associated with higher-grade tumors, a trend toward increased risk of positive surgical margins, and higher biochemical failure rates among men treated with radical prostatectomy in several large studies of prostate cancer patients.
2,4
These observations led us to speculate that obesity may be associated with enhanced levels of angiogenic factors, which Endothelial growth factors in obesity JV Silha et al may either be directly involved in the pathogenesis of obesity or more likely, a consequence of increased adiposity.
To address this issue we measured factors involved in angiogenesis in a large group of subjects (N ¼ 100) with BMI in range from 17 to 51. Here we report for the first time the sexual dimorphism in the serum concentrations of VEGF-C, VEFG-D and angiopoietin-2. Furthermore, we have also demonstrated that VEGF-C, VEGF-D, sVEGFr2, angiopoietin-2, angiogenin and endostatin are significantly elevated in either overweight or obese subjects compared to lean controls. Although these factors have been implicated in the regulation of angiogenesis, the exact contribution of each of these factors to the overall angiogenic capacity of serum is Figure 1 Serum concentrations of vascular growth factors and related peptides in lean (L), overweight (Ow) and obese (Ob)subjects. The significant difference between the genders within the one category is indicated as #, representing Po0.05. Significant differences between the lean control group and the overweight and obese groups of the same gender are indicated as *Po0.05 and **Po0.01, respectively. Endothelial growth factors in obesity JV Silha et al not yet elucidated and their role in adipose tissue angiogenesis is unclear. In addition, several of these factors have other important functions and it is not clear whether their angiogenic activity measured in in vitro assays is important in vivo. For example, HGF or scatter factor is a mescenchymederived growth factor that is important in liver development. It is also a potent mitogen for endothelial cells acting through the tyrosine kinase receptor encoded by the MET protooncogene. 28 It is expressed in preadipocytes. In vitro,
HGF induces endothelial cells to proliferate and migrate. 28 It also has potent angiogenic effect in vivo, in the rabbit cornea, where it promotes neovascularization. 28 Elevated HGF concentrations are found in hypertensive individuals with target-organ damage, 11 in diabetics 29 and in patients with coronary and peripheral arterial disease. 30, 12 A positive association between plasma HGF concentrations and carotid arterial atherosclerosis and dilation has also been reported. 31 HGF has recently been reported to be elevated in obese subjects, 15 however, the population studied was more markedly obese (mean BMI ¼ 48 kg/m 2 ) compared to our obese population (mean BMIB39 kg/m 2 ). In contrast, in the study reported by Yamamoto et al, 31 that did not include morbidly obese individuals, no relationship was found between HGF levels and BMI. This latter finding would be consistent with our observations reported here. The VGEF family of proteins is important for the development of blood vessels during embryogenesis and in pathological conditions such as tumorigenesis. 32 VEGF is a heparin-binding glycoprotein with angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. 33 Serum VEGF levels were found to positively correlate with BMI and visceral fat mass in a group of 38 overweight and obese individuals. 14 Since insulin suppresses VEGF expression, 34 increased VEGF levels in overweight subjects may indicate some degree of insulin resistances. However, we found only a weak association with BMI (P ¼ 0.04) in our larger group of subjects. In contrast, serum levels of the other members of the VEGF family, VEGF-C and -D were significantly elevated in the obese group and showed a strong positive correlation with BMI. To our knowledge there have been no previous reports of elevated VEGF-C and VEGF-D levels in obesity. VEGF-C and -D like VEGF stimulate angiogenesis in various in vivo models, 35, 36 however, they also appear to be very important in lymphangiogenesis. 37, 38 Tumor cells that overexpress either VEGF-C or -D enhanced lymphangiogenesis and have a more metastatic phenotype. 39, 40 The VEGF family of growth factors interacts with a variety of cell surface receptor tyrosine kinases. At least two of these receptors, VEGF R1 and R2, exist as circulating fragments that can bind their ligand and inhibit angiogenesis. 41 Here we report for the first time that sVEGF-R2 levels are elevated in obese patients. Elevated levels would tend to inhibit the increased levels of VEGFs present in serum from obese subjects.
Angiogenin is a member of the ribonuclease superfamily and it was initially isolated from the conditioned medium of a human colon cancer cell line, however, it is known to be expressed by a wide variety of normal cells including vascular endothelial cells, smooth muscle cells and fibroblasts. 42 It is therefore not unexpected, although previously unreported, that angiogenin levels are increased in obesity. We found a strong correlation between BMI and angiogenin levels suggesting that adipose tissue itself may contribute to circulating angiogenin concentrations. Angiogenin has strong angiogenic activity in vivo and its angiogenic activity appears to be critical for the maintenance and support of tumor growth. 43 Angiopoietin-2 is a secreted glycoprotein, expressed by endothelial cells as well as a variety of other cell type that plays a critical role in vascular development. It mediates its effect via inhibition of angiopoietin-1-mediated phosphorylation of Tie2. 44 It has angiogenic effects including stimulation of chemotaxis and tube-like structure formation in cultured brain capillaries. 44 However, under certain circumstances angiopoietin-2 can also have antiangiogenic effects. For example, transgenic overexpression of angiopoietin-2 leads to disruption of embryonic blood vessel formation, a phenotype similar to that of Tie-2 knockouts and that is consistent with its role as an angiopoietin-1/Tie-2 inhibitor. 45 Angiopoietin-2 been implicated in cancer development due to its role in angiogenesis. Elevated levels are found in patients with a variety of cancers and levels correlate with advance tumor stage progression and poor prognosis 46 . To our knowledge there are no previous reports Figure 2 Correlation between serum angiogenin levels and log BMI in lean and obese subjects. Open symbols depict male subjects whereas female subjects are depicted as solid symbols. The solid line indicates the regression line for the correlation between angiogenin levels and log BMI when all subjects were considered together. The regression lines for this correlation in male and female subjects are also shown.
Endothelial growth factors in obesity JV Silha et al of angiopoietin-2 levels in obesity. Here we report sexual dimorphism in serum angiopoietin-2 levels and also the observation that angiopoietin-2 is increased in obesity. Endostatin, a C-terminal fragment of collagen XVIII, functions as a potent inhibitor of angiogenesis and endothelial cell migration. It interacts with receptors, possibly integrins on the endothelial cells 47 and downregulates many signaling pathways in human microvascular endothelium associated with proangiogenic activity. 48 Here we report that endostatin levels are higher in overweight and obese males compared to lean subjects. This contrasts with the report by Seida et al, 49 who reported similar endostatin levels in overweight and normal weight Japanese men. Recently, adiponectin has been shown to significantly inhibit tumor growth in a mouse model. 8 This impaired tumor growth was found to be associated with decreased neovascularization. We observed a weak negative correlation between angiogenin and adiponectin (r ¼ À0.31, P ¼ 0.002). There were no significant correlations between adiponectin and any of the other vascular growth factors that we measured. This suggests that these other factors are not important effectors of adiponectin's antiangiogenic action. It remains to be determined whether the antiangiogenic effects of adiponectin are mediated in part via angiogenin or other factors as well as by direct actions on endothelial cells. In summary, we have demonstrated increased levels of vascular growth factors and also angiogenesis inhibitor endostatin in obese subjects. Although it remains to be proven, it is likely that adipose tissue itself contributes to the elevated circulating levels of these factors. Further studies are necessary to determine whether the apparent sexual dimorphism observed in the levels of some of these factors is attributable to the effects of sex hormones or differences in fat distribution in male and female subjects.
